Relay Therapeutics
Prior to joining Relay Therapeutics, Mahesh Padval was vice president of pharmaceutical sciences and product development at Verastem, Inc. There, he was responsible for preclinical development, CMC and clinical pharmacology activities in support of company’s development programs through non-clinical, clinical development and regulatory filings, including the recent approval and commercial launch of COPIKTRA™.
Prior to Verastem, Mahesh held roles of increasing responsibility at Zalicus, Inc., culminating in his role as vice president of preclinical development and formulations. He also held roles at Charles River Discovery and Development Services and Genzyme Transgenics Corporation.
Mahesh holds a Ph.D. and M.S. in industrial pharmacy from Massachusetts College of Pharmacy, and a Bachelor of Pharmacy from the University of Bombay, India.
Relay Therapeutics
1 followers
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology.